SPY431.24-2.14 -0.49%
DIA341.55+0.09 0.03%
IXIC13,352.78-189.34 -1.40%

BRIEF-Codex Dna Inc - On Dec 22, 2021, Co Entered Into Research Collaboration And License Agreement With Pfizer Inc

reuters.com · 12/29/2021 08:30
BRIEF-Codex Dna Inc - On Dec 22, 2021, Co Entered Into Research Collaboration And License Agreement With Pfizer Inc

- Codex DNA Inc DNAY:

  • CODEX DNA INC - ON DEC 22, 2021, CO ENTERED INTO RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER INC

  • CODEX DNA INC - CO, PFIZER AGREED TO COLLABORATE TO DEVELOP IMPROVEMENTS TO CO’S EXISTING PROPRIETARY BIOXP PLATFORM

  • CODEX DNA INC - UNDER AGREEMENT, PFIZER TO MAKE UPFRONT PAYMENT TO CO OF $8 MILLION

  • CODEX DNA - IF CO MEETS CERTAIN MILESTONES, CO WILL BE ELIGIBLE TO GET ADDITIONAL $10 MILLION IN PAYMENTS FROM PFIZER RELATED TO CONDUCT OF RESEARCH AND DEVELOPMENT PROGRAM

  • CODEX DNA INC - PFIZER HAS AGREED TO PAY CO UP TO $60 MILLION IN SALES MILESTONES FOR PRODUCTS (OTHER THAN EXCLUSIVE PRODUCTS)

  • CODEX DNA INC - PFIZER HAS AGREED TO PAY CO UP TO UP TO $180 MILLION IN SALES MILESTONES FOR EXCLUSIVE PRODUCTS

  • CODEX DNA - PFIZER TO MAKE MILESTONE PAYMENTS TO CO WITH EACH PRODUCT BEING ELIGIBLE FOR PAYMENTS UP TO $35 MILLION

  • CODEX DNA - PROVIDED AGREEMENT REMAINS IN PLACE, PFIZER WILL PAY ESCALATING ROYALTIES FROM LOW TO MID-FRACTION OF ONE PERCENT OF NET SALES OF PRODUCTS

  • CODEX DNA - PFIZER TO MAKE MILESTONE PAYMENTS TO CO WITH FIRST EXCLUSIVE PRODUCT IN EACH EXCLUSIVE FIELD BEING ELIGIBLE FOR PAYMENT OF UP TO $55 MILLION

Source text for Eikon: [https://bit.ly/3z6YDWt]

Further company coverage: DNAY


((Reuters.Briefs@thomsonreuters.com;))